Business
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year --\n -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental Glomerulosclerosis (FSGS) expected Q2 -- -- Completed enrollment of the AURORA clinical trial of avacopan in Hidradenitis Suppurativa (HS), with topline data expected Q3 -- -- ACCOLADE clinical trial of avacopan in C3 Glomerulopathy (C3G) on track to report topline data expected by year-end -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company's recent corporate highlights. \"In the face of this global infection pandemic, we pause in sympathy for those suffering while we are reminded of the deep importance of our mission,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “A central tenet for our new medicines is ‘do not immune suppress’, and the current crisis provides a stark reminder of exactly why this is so important. The use of immune suppressive therapies, which are the current standard-of-care for autoimmune diseases like ANCA vasculitis, puts people who are already struggling with serious, life threatening conditions at additional risk for infectious disease.” “We at ChemoCentryx are entirely devoted to a different and, we believe, better approach: highly targeted, non-immunosuppressive medicines such as avacopan. Such medicines are entirely unlike the current immune-destroying regimen of high doses of prednisone combined with other immune system dampeners. Our mission at ChemoCentryx continues with increased urgency. We are actively preparing our NDA submission to the FDA following the positive results of the Phase III ADVOCATE trial of avacopan for the treatment of ANCA vasculitis. We are also looking forward to topline data from our CCR2 inhibitor CCX140 in FSGS patients, as well as the rest of our data readouts expected this year in our ‘2020 4-Sight’ plan. For example, enrollment is complete with over 400 patients in the Phase II AURORA clinical trial of avacopan in HS, and we also expect to report topline data from our ACCOLADE trial of avacopan in C3G by the end of the year. Our missio...